SR-3029

highly selective casein kinase 1delta/1epsilon inhibitor with potent antiproliferative properties; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Aceti, Massimiliano: 1 article (01/2020)
2.	Bayle, Simon: 1 article (01/2020)
3.	Duckett, Derek: 1 article (01/2020)
4.	Frydman, Sylvia M: 1 article (01/2020)
5.	Grant, Wayne: 1 article (01/2020)
6.	McDonald, Patricia: 1 article (01/2020)
7.	Monastyrskyi, Andrii: 1 article (01/2020)
8.	Nieto, Ainhoa: 1 article (01/2020)
9.	Quereda, Victor: 1 article (01/2020)
10.	Roush, William R: 1 article (01/2020)

1.	Disease Progression 12/01/2023 - "Finally, sensitivity of multiple myeloma patient specimens to SR-3029 correlated with elevated expression of mitochondrial genes, and RNA-seq from 687 multiple myeloma patient samples revealed that increased CSNK1D, CSNK1E, and OxPhos genes correlate with disease progression and inferior outcomes. "
2.	Multiple Myeloma 12/01/2023 - "Specifically, the dual CK1δ/CK1ε inhibitor SR-3029 had potent in vivo and ex vivo anti-multiple myeloma activity, including against primary multiple myeloma patient specimens. " 12/01/2023 - "Finally, sensitivity of multiple myeloma patient specimens to SR-3029 correlated with elevated expression of mitochondrial genes, and RNA-seq from 687 multiple myeloma patient samples revealed that increased CSNK1D, CSNK1E, and OxPhos genes correlate with disease progression and inferior outcomes. "
3.	Urinary Bladder Neoplasms (Bladder Cancer) 01/01/2020 - "The combination of SR-3029 with gemcitabine induced synergistic antiproliferative activity and enhanced apoptosis in both pancreatic and bladder cancer cells. " 01/01/2020 - "We assessed the antitumor effects of genetically silencing or pharmacologically inhibiting CK1δ using our in-house CK1δ small-molecule inhibitor SR-3029, either alone or in combination with gemcitabine, on the proliferation and survival of pancreatic and bladder cancer cell lines and orthotopic mouse models. "